Toxicodendron is a genus of flowering plants in the sumac family, Anacardiaceae. It contains trees, shrubs and woody vines, including poison ivy, poison oak, and the lacquer tree. All members of the genus produce the skin-irritating oil urushiol, which can cause a severe allergic reaction. The generic name is derived from the Greek words τοξικός (toxikos), meaning "poison," and δένδρον (dendron), meaning "tree". The best known members of the genus in North America are poison ivy (T. radicans), practically ubiquitous throughout most of eastern North America, and western poison oak, similarly ubiquitous throughout much of the western part of the continent.
Toxicodendron radicans, commonly known as eastern poison ivy or poison ivy, is an allergenic Asian and Eastern North American flowering plant in the genus Toxicodendron. The species is well known for causing urushiol-induced contact dermatitis, an itchy, irritating, and sometimes painful rash, in most people who touch it. The rash is caused by urushiol, a clear liquid compound in the plant's sap. The species is variable in its appearance and habit, and despite its common name, it is not a true ivy (Hedera), but rather a member of the cashew and pistachio family (Anacardiaceae). T. radicans is commonly eaten by many animals and the seeds are consumed by birds, but poison ivy is most often thought of as an unwelcome weed. It is a different species from western poison ivy, T. rydbergii, which has similar effects.
Urushiol is an oily mixture of organic compounds with allergenic properties found in plants of the family Anacardiaceae, especially Toxicodendronspp., Comocladia spp. (maidenplums), Metopium spp. (poisonwood), and also in parts of the mango tree as well as the fruit of the cashew tree. In most individuals, urushiol causes an allergic skin rash on contact, known as urushiol-induced contact dermatitis.
Haptens are small molecules that elicit an immune response only when attached to a large carrier such as a protein; the carrier may be one that also does not elicit an immune response by itself. The mechanisms of absence of immune response may vary and involve complex immunological interactions, but can include absent or insufficient co-stimulatory signals from antigen-presenting cells.
Contact dermatitis is a type of acute or chronic inflammation of the skin caused by exposure to chemical or physical agents. Symptoms of contact dermatitis can include itchy or dry skin, a red rash, bumps, blisters, or swelling. These rashes are not contagious or life-threatening, but can be very uncomfortable.
Toxicodendron diversilobum, commonly named Pacific poison oak or western poison oak, is a woody vine or shrub in the sumac family, Anacardiaceae. It is widely distributed in western North America, inhabiting conifer and mixed broadleaf forests, woodlands, grasslands, and chaparral biomes. Peak flowering occurs in May. Like other members of the genus Toxicodendron, T. diversilobum causes itching and allergic rashes in most people after contact by touch or smoke inhalation. Despite its name, it is not closely related to oaks.
Antipruritics, abirritants, or anti-itch drugs, are medications that inhibit the itching often associated with sunburns, allergic reactions, eczema, psoriasis, chickenpox, fungal infections, insect bites and stings like those from mosquitoes, fleas, and mites, and contact dermatitis and urticaria caused by plants such as poison ivy or stinging nettle. It can also be caused by chronic kidney disease and related conditions.
Toxicodendron vernix, commonly known as poison sumac, or swamp-sumach, is a woody shrub or small tree growing to 9 metres (30 feet) tall. It was previously known as Rhus vernix. This plant is also known as thunderwood, particularly where it occurs in the southern United States. All parts of the plant contain a resin called urushiol that causes skin and mucous membrane irritation to humans. When the plant is burned, inhalation of the smoke may cause the rash to appear on the lining of the lungs, causing extreme pain and possibly fatal respiratory difficulty.
Urushiol-induced contact dermatitis is a type of allergic contact dermatitis caused by the oil urushiol found in various plants, most notably sumac family species of the genus Toxicodendron: poison ivy, poison oak, poison sumac, and the Chinese lacquer tree. The name is derived from the Japanese word for the sap of the Chinese lacquer tree, urushi. Other plants in the sumac family also contain urushiol, as do unrelated plants such as Ginkgo biloba.
Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug. The entire process – from concept through preclinical testing in the laboratory to clinical trial development, including Phase I–III trials – to approved vaccine or drug typically takes more than a decade.
Allergic contact dermatitis (ACD) is a form of contact dermatitis that is the manifestation of an allergic response caused by contact with a substance; the other type being irritant contact dermatitis (ICD).
Poison ivy is a type of allergenic plant in the genus Toxicodendron native to Asia and North America. Formerly considered a single species, Toxicodendron radicans, poison ivies are now generally treated as a complex of three separate species: Toxicodendron radicans, Toxicodendron rydbergii, and Toxicodendron orientale. They are well known for causing urushiol-induced contact dermatitis, an itchy, irritating, and sometimes painful rash, in most people who touch it. The rash is caused by urushiol, a clear liquid compound in the plant's sap. They are variable in appearance and habit, and despite its common name, it is not a "true" ivy (Hedera), but rather a member of the cashew and pistachio family (Anacardiaceae). T. radicans is commonly eaten by many animals, and the seeds are consumed by birds, but poison ivy is most often thought of as an unwelcome weed.
Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13.
Mahmoud A. ElSohly is an Egyptian-born American pharmacologist known for his research into cannabis. He is a professor of pharmaceutics and research professor at the Research Institute of Pharmaceutical Sciences at the University of Mississippi. He is also the director of the University of Mississippi's Marijuana Research Project, the only legal source of marijuana that can be used for medical research in the United States. He is also the president and laboratory director of ElSohly Laboratories, Incorporated.
Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.
COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc. It is a peptide vaccine.
AWcorna, originally termed ARCoV and also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science. In contrast to other mRNA COVID vaccines, such as those by Pfizer-BioNtech and Moderna, this vaccine primarily targets the Sars-CoV-2 receptor-binding domain of the spike protein, rather than the entire spike protein. It is approved for Phase III trials in China, Mexico, Indonesia, and Nepal.
Corbevax is a protein subunit COVID-19 vaccine developed by Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine in Houston, Texas and Dynavax technologies based in Emeryville, California. It is licensed to Indian biopharmaceutical firm Biological E. Limited (BioE) for development and production.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:
